Ti Hwei How

Ti Hwei How is the vice president of international oncology and market access at AstraZeneca. Prior to this, he was the country president of AstraZeneca Singapore. He also currently serves as a member of the Singapore Pharmacy Council, the National University of Singapore Pharmacy Programme Advisory Board, and the Ngee Ann Polytechnic Life Sciences and Chemical Technology Advisory Committee.

Latest Articles

Opinion: Scaling up early detection is vital to reduce lung cancer mortality

almost 2 years ago // Sponsored by AstraZeneca

Lung cancer remains the leading cause of cancer death, but screening programs could increase the five-year survival rate, on average, by 73%, says AstraZeneca’s vice president for international oncology and market access, Ti Hwei How.

Opinion: Asia needs a tailored approach to lung cancer management

over 2 years ago // Sponsored by AstraZeneca

Lung cancer patients in Asia are increasingly younger, non-smokers, and women, requiring tailored approaches to screening, diagnosis, and treatment. AstraZeneca’s Ti Hwei How weighs in.

Opinion: A cancer revolution is on the cusp — if equity is improved

over 3 years ago // Sponsored by AstraZeneca

While cancer treatment developments are moving quickly, quality care is only available in 15% of low- and middle-income countries. VP Oncology International's Ti Hwei and VP Medical International Pei-Chieh stress the need to address barriers to equitable access.

See all articles by Ti Hwei How